Leading the development of MOSkin, the world's most advanced and cost-effective medical radiation sensor technology, was personal for Distinguished Professor Anatoly Rozenfeld.
The University of Wollongong professor's parents passed away from cancer
Finding the best treatment or improved treatment has since been his "important role in society".
"Also, to simply help people to live longer and enjoy life even with cancer. It is always good to see that the outcome of your research is more than a published paper," Professor Rozenfeld said.
On Thursday the "next generation technology" developed by researchers at UOW's world leading Centre for Medical Radiation Physics (CMRP), was launched.
Prof Rozenfeld said MOSkin was a cost effective assurance tool that precisely measures radiation dose and dose rate, in addition to beam monitoring of transmitted radiation.
"MOSkin radiation sensor technology provides peace of mind for the patient and physician," he said.
"It is the only real-time radiation sensor that provides an accurate measure of dose to the skin during radiation therapy treatment or diagnostic radiology procedures."
MOSkin radiation sensor technology provides peace of mind for the patient and physician.Distinguished Professor Anatoly Rozenfeld
Radiation is widely used for procedures such as angiograms and diagnostic and interventional radiology scans while radiotherapy is part of the treatment plan for up to 50 per cent of all cancer patients.
These procedures currently rely on techniques that offer limited accuracy and reliability to measure specific radiation dose and dose rate.
While current treatments are usually safe and effective, by some estimates, up to half of patients who receive radiotherapy will suffer some level of unwanted organ or tissue damage.
MOSkin technology has been proven in multiple successful clinical tests in Australia, Europe, Brazil and Malaysia to be suitable for real-time radiation measurements.
"It was a long journey, more than a decade, and demanded a multi-skilled team and a lot of hard work, not just from me, but from all my CMRP team," Prof Rozenfeld said.
Electrogenics Laboratories Ltd has been granted the exclusive global licence for MOSkin.
A pre-IPO offering is underway seeking up to $4 million for up to 40 per cent shareholding. The company has plans to list on the Australian Stock Exchange within 12 to 18 months.
Electrogenics chairman Kim Lyle said MOSkin will be manufactured in Australia and commercialised globally.
"This is a very exciting time for all of us at Electrogenics," Mr Lyle said.